SOX2 Oncogenes Amplified and Operate to Activate AKT Signaling in Gastric Cancer and Predict Immunotherapy Responsiveness

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2014 Apr 23

PMID 24752338

Citations 16

Authors

Yajun Tian

Xin Jia

Shengxiang Wang

Yongsheng Li

Peng Zhao

Da Cai

Zequan Zhou

Junmin Wang

Yi Luo

Maosheng Dong

Affiliations

Soon will be listed here.

Abstract

Introduction: Gastric cancer is the second leading cause of cancer mortality in the world. Whether the oncogene, amplified on chromosome 3q26, SOX2, a master transcriptional regulator of stemness, operate to drive strong growth phenotype in gastric cancer were unknown.

Materials And Methods: The gene expression changes of SOX2 in human gastric cancer tissues compared with non-cancerous tissues was detected using real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis and immunohistochemistry, which identified the gene overexpression of SOX2 in gastric cancer. Moreover, we discovered that SOX2 promoted cancer cell proliferation in vitro/vivo and SOX2 expression correlated with elevated AKT phosphorylation in gastric cancer, while the AKT phosphorylation was required for SOX2's oncogenic effects. Next, our data point to the usefulness of SOX2 overexpression, as a new predictive marker for responsiveness to trastuzumab.

Conclusion: SOX2 is a commonly activated tumor promoter that activate AKT signaling in gastric cancer and a new predictive marker for targeted therapy.

Citing Articles

Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma.

Tseng C, Lu P, Wang Y, Chang J J Pers Med. 2022; 12(1).

PMID: 35055392 PMC: 8780877. DOI: 10.3390/jpm12010077.

CLC-3 and SOX2 regulate the cell cycle in DU145 cells.

Chen J, Wang F, Lu Y, Yang S, Chen X, Huang Y Oncol Lett. 2020; 20(6):372.

PMID: 33154770 PMC: 7608052. DOI: 10.3892/ol.2020.12235.

Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer.

Shi Y, Wang Z, Zhu X, Chen L, Ma Y, Wang J Int J Clin Oncol. 2019; 25(1):89-99.

PMID: 31506750 DOI: 10.1007/s10147-019-01532-9.

Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.

He C, Liu C, Wang L, Sun Y, Jiang Y, Hao Y Cell Death Dis. 2019; 10(2):65.

PMID: 30683853 PMC: 6347630. DOI: 10.1038/s41419-019-1347-1.

Association of High Expression Levels of SOX2, NANOG, and OCT4 in Gastric Cancer Tumor Tissues with Progression and Poor Prognosis.

Basati G, Mohammadpour H, Emami Razavi A J Gastrointest Cancer. 2019; 51(1):41-47.

PMID: 30628031 DOI: 10.1007/s12029-018-00200-x.

References

Aksoy I, Jauch R, Eras V, Chng W, Chen J, Divakar U . Sox transcription factors require selective interactions with Oct4 and specific transactivation functions to mediate reprogramming. Stem Cells. 2013; 31(12):2632-46. DOI: 10.1002/stem.1522. View

Konecny G, Pegram M, Venkatesan N, Finn R, Yang G, Rahmeh M . Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66(3):1630-9. DOI: 10.1158/0008-5472.CAN-05-1182. View

Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y . Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2006; 59(6):795-805. DOI: 10.1007/s00280-006-0337-z. View

Cho H, Mason K, Ramyar K, Stanley A, Gabelli S, Denney Jr D . Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421(6924):756-60. DOI: 10.1038/nature01392. View

Price-Schiavi S, Jepson S, Li P, Arango M, Rudland P, Yee L . Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002; 99(6):783-91. DOI: 10.1002/ijc.10410. View

Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L . HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003; 22(21):3205-12. DOI: 10.1038/sj.onc.1206394. View

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

Agus D, Akita R, Fox W, Lewis G, Higgins B, Pisacane P . Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002; 2(2):127-37. DOI: 10.1016/s1535-6108(02)00097-1. View

Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis L . Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010; 5(2):e9112. PMC: 2817751. DOI: 10.1371/journal.pone.0009112. View

10.

Geyer C, Forster J, Lindquist D, Chan S, Romieu C, Pienkowski T . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26):2733-43. DOI: 10.1056/NEJMoa064320. View

11.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

12.

Tompkins D, Besnard V, Lange A, Keiser A, Wert S, Bruno M . Sox2 activates cell proliferation and differentiation in the respiratory epithelium. Am J Respir Cell Mol Biol. 2010; 45(1):101-10. PMC: 3145063. DOI: 10.1165/rcmb.2010-0149OC. View

13.

Bang Y, Kim Y, Yang H, Chung H, Park Y, Lee K . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813):315-21. DOI: 10.1016/S0140-6736(11)61873-4. View

14.

Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M . Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001; 93(24):1852-7. DOI: 10.1093/jnci/93.24.1852. View

15.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

16.

Pauletti G, Godolphin W, Press M, Slamon D . Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996; 13(1):63-72. View

17.

Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J . Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99(8):628-38. DOI: 10.1093/jnci/djk134. View

18.

Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D . SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010; 5(1):e8960. PMC: 2813300. DOI: 10.1371/journal.pone.0008960. View

19.

Li Y, Pan Y, Wei Y, Cheng X, Zhou B, Tan M . Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004; 6(5):459-69. DOI: 10.1016/j.ccr.2004.09.027. View

20.

Kute T, Lack C, Willingham M, Bishwokama B, Williams H, Barrett K . Development of Herceptin resistance in breast cancer cells. Cytometry A. 2004; 57(2):86-93. DOI: 10.1002/cyto.a.10095. View